Daniel R. Chevallard

Daniel R. Chevallard, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Viracta Therapeutics, Inc. and LENZ Therapeutics, Inc. We count 16 filings; the first trade dates from 28 May 2021 and the latest from 27 March 2026.

Market trades split into 3 purchases (€102k) and 1 sale (€1,697). The net balance comes to €101k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 12 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

The median purchase comes to €46k. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 30 March 2026, reports an open-market purchase of €56k in LENZ Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.